ClinicalTrials.gg
RecruitingNCT07474025PROCPHGPUpdated Oct 26, 2026

Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study

An observational study in Peritoneal (Metastatic) Cancer, Colorectal Cancer and Colorectal (Colon or Rectal) Cancer, sponsored by Jules Bordet Institute. Recruiting at 2 sites in Belgium. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Jules Bordet Institute · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 26, 2026Now RecruitingPrimary outcomes revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
Up to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 262 studies in Neoplasm Metastasis with a site in Belgium — 39 open to participants now, 77 under way, 31 of them phase 3. Neoplasm Metastasis · Belgium.

Planned enrollment
13th of 14
30 · median 62
Started
2026
with 3 others
Observational
14 of 262
4 open now
Primary completion
2028-12
later than 65 of 76 live
Registered
261st of 262
by date
Lead sponsor
7 of 262
Jules Bordet Institute

Among the 262 studies in Neoplasm Metastasis with a site in Belgium, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 65 of the 76 other live ones, and was the 261st registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

39 of the 262 studies in Neoplasm Metastasis with a site in Belgium are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: Up to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Neoplasm Metastasis with a site in Belgium, or all of them as a file.
02

Study summary

his prospective, single-center observational pilot study evaluates whether peritoneal histopathological growth patterns can be assessed on limited excisional biopsies obtained during staging laparoscopy in adults with suspected or confirmed colorectal peritoneal metastases. The study primarily evaluates agreement between the dominant histopathological growth pattern identified on laparoscopic biopsy and that identified on subsequent operative specimens.

One to three peritoneal deposits will be sampled during staging laparoscopy. When surgery proceeds, up to three peritoneal deposits will be collected from the operative specimen, preferably from corresponding Peritoneal Cancer Index regions. Two pathologists, blinded to clinical information, specimen timing, and each other's assessments, will independently estimate the proportions of pushing and infiltrating growth patterns.

Histopathological growth pattern findings will not be used to guide clinical management. Biopsy evaluability, interobserver reproducibility, interlesional heterogeneity, and exploratory associations with clinical and surgical characteristics will also be assessed.

Read the detailed description

Peritoneal histopathological growth patterns (HGPs) describe the morphological interface between metastatic tumor deposits and the surrounding peritoneal tissue and may provide biological information that is not captured by conventional clinical or pathological variables. This prospective, single-center observational pilot study aims to determine whether peritoneal HGPs can be reliably assessed on limited biopsies obtained during staging laparoscopy and whether the dominant HGP identified on these biopsies agrees with that identified on subsequent cytoreductive surgery (CRS) specimens. Thirty adult patients with colorectal peritoneal metastases who are scheduled to undergo both staging laparoscopy and cytoreductive surgery, with or without hyperthermic intraperitoneal chemotherapy, will be prospectively enrolled.

During staging laparoscopy, one to three peritoneal deposits will be sampled using cold scissors. CRS will subsequently be performed within eight weeks, without interval systemic anticancer treatment. During CRS up to three additional peritoneal deposits will be collected, preferably from the same PCI regions or anatomical compartments as the laparoscopic samples. Two pathologists, blinded to clinical information, specimen timing, and each other's assessments, will independently estimate the proportions of pushing and infiltrating HGP at the tumor-peritoneum interface according to a prespecified histopathological standard operating procedure. The primary outcome will be patient-level agreement in dominant HGP classification between staging-laparoscopy biopsies and cytoreductive surgery specimens. Secondary outcomes will include biopsy evaluability, interobserver agreement, agreement in continuous HGP proportions, interlesional heterogeneity, and exploratory associations between HGP and primary-tumor characteristics, PCI, and completeness of cytoreduction. Overall survival and disease-free survival will be explored descriptively; however, the study is not powered to establish the prognostic value or clinical utility of HGP. HGP assessments will not be used to guide treatment decisions, which will remain based on standard multidisciplinary clinical evaluation.

03

Conditions studied

  • Peritoneal (Metastatic) Cancer
  • Colorectal Cancer
  • Colorectal (Colon or Rectal) Cancer
  • Histopathological Growth Patterns (HGPs)

Keywords

  • Peritoneal cancer
  • Colorectal cancer
  • Histopathological Growth Patterns
04

Who can participate

Ages eligible
Up to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients with histologically confirmed colorectal cancer and suspected or confirmed peritoneal metastases who undergo surgical evaluation or treatment (staging laparoscopy and/or cytoreductive surgery ± HIPEC) as part of routine clinical care at participating centers. Peritoneal metastasis tissue samples obtained during these procedures are used for histopathological analysis to evaluate histological growth patterns and their association with clinicopathological characteristics and clinical outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • confirmed colorectal adenocarcinoma
  • Suspected or confirmed peritoneal from colorectal cancer based on imaging or prior clinical evaluation
  • Patients undergoing staging laparoscopy and/or cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) as part of standard clinical care
  • Availability of peritoneal metastasis tissue samples suitable for histopathological analysis
  • Written provided for participation in the study

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Peritoneal originating from non-colorectal primary tumors
  • Absence of available or adequate peritoneal metastasis tissue samples for histological growth pattern analysis
  • Patients who decline or withdraw
  • Patients unable to provide informed consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with colorectal peritoneal metastases

    Adult patients with histologically confirmed colorectal cancer and suspected or confirmed peritoneal metastases undergoing standard-of-care surgical evaluation or treatment (staging laparoscopy and/or cytoreductive surgery ± HIPEC). Peritoneal metastasis tissue samples obtained during routine clinical care are analyzed histologically to assess histological growth patterns and their association with clinical and pathological outcomes. No experimental intervention is performed as part of the study.

06

What researchers measure

Primary outcomes

  1. Concordance of peritoneal histopathological growth pattern classification between staging-laparoscopy biopsies and subsequent cytoreductive surgery specimens.

    Histological characterization of colorectal peritoneal metastases according to predefined histological growth pattern criteria (e.g., pushing, infiltrative/replacement, or mixed patterns) on hematoxylin and eosin (H\&E)-stained tissue sections obtained from peritoneal biopsies or surgical specimens. The proportion of each HGP type will be determined.

    Time frame: At time of histopathological analysis of surgical or laparoscopic biopsy specimens (baseline, during initial surgical evaluation).

Secondary outcomes

  1. Association between histological growth patterns and peritoneal disease burden

    Assessment of the relationship between histological growth pattern and extent of peritoneal disease as measured by the Peritoneal Cancer Index (PCI).

    Time frame: At time of surgery or staging laparoscopy.

  2. Association between histological growth patterns and histopathological tumor characteristics

    Evaluation of associations between HGP and tumor-related characteristics including differentiation grade, molecular markers, and other pathological features of colorectal cancer.

    Time frame: At time of histopathological analysis.

  3. Association between histological growth patterns and survival outcomes

    Evaluation of the relationship between HGP and clinical outcomes including overall survival and progression-free survival.

    Time frame: Up to 2 years after surgery or diagnosis of peritoneal metastases.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly due to patient confidentiality considerations and institutional data protection policies in accordance with applicable regulations (including GDPR).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 33 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 16, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 Belgium)
  • Institut Jules Bordet · Brussels, Belgium
  • Hub Bordet · Brussels, Belgium
Show 1 removed
  • Hub Bordet · Brussels, Belgium
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Distribution of histological growth patterns (HGP) in colorectal peritoneal metastasesNow Concordance of peritoneal histopathological growth pattern classification between staging-laparoscopy biopsies and subsequent cytoreductive surgery specimens.Time frame: At time of histopathological analysis of surgical or laparoscopic biopsy specimens (baseline, during initial surgical evaluation).
Oct 26, 2026
Contact
Study contact changed: g•••@hubruxelles.be · •••3111→g•••@hubruxelles.be · •••3111. See the current contact
Oct 26, 2026
Title
Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses→Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    2 sites added, 1 site removed
    Show 2 added (2 Belgium)
    • Institut Jules Bordet · Brussels, Belgium
    • Hub Bordet · Brussels, Belgium
    Show 1 removed
    • Hub Bordet · Brussels, Belgium
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Distribution of histological growth patterns (HGP) in colorectal peritoneal metastasesNow Concordance of peritoneal histopathological growth pattern classification between staging-laparoscopy biopsies and subsequent cytoreductive surgery specimens.Time frame: At time of histopathological analysis of surgical or laparoscopic biopsy specimens (baseline, during initial surgical evaluation).
    Contact Study contact changed: g•••@hubruxelles.be · •••3111→g•••@hubruxelles.be · •••3111. See the current contact
    Title Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses→Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study
    + 2 other changes: date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07474025
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Mar 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Gabriel Professor Liberale, MD, pHD
Contact
gabriele.liberale@hubruxelles.be
+32 2 541 31 11

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion